ViCentra, a European medical device company redefining insulin delivery for people with diabetes, has announced the successful close of an upsized 85 million USD Series D financing led by new investor Innovation Industries, a leading European deeptech venture capital firm, with matching participation from existing investors Partners in Equity and Invest-NL, alongside continued support from EQT Life Sciences and Health Innovations.
With fresh funding, ViCentra will accelerate manufacturing scale-up, launch the next-generation Kaleido 2 patch pump in Europe, and prepare for U.S. market entry. Kaleido is the smallest, lightest, and most precise insulin patch pump in its class, uniquely designed as a lifestyle product that is discreet, intuitive, and personalised.
Designed to feel more like personal technology than a traditional medical device according to the company, Kaleido features premium materials and customisable aluminium shells in ten colour options. The device is also integrated with Diabeloop’s self-learning automated insulin delivery algorithm and compatible with the Dexcom CGM sensor.
Strong initial commercial uptake of Kaleido in Germany, France, and the Netherlands has driven demand beyond initial expectations says ViCentra. This financing enables the company to scale the business for rapid revenue acceleration.
“Kaleido is a true disruptor – small, discreet, featherlight, and beautifully designed technology. It empowers people with diabetes by offering a more personal and selective choice in both function and style. Built with understanding and precision, it honours those who live with diabetes every day. With this funding, we can meet surging European demand and accelerate our entry into the U.S. market. This is a pivotal moment for both the company and the community we serve,” said Tom Arnold, Chief Executive Officer at ViCentra.
The global insulin delivery market is one of the largest and fastest growing medical device segments says the company, driven by the rising prevalence of diabetes and increasing demand for solutions that blend clinical effectiveness with everyday usability. The insulin pump market alone is projected to reach over 14 billion USD by 2034. Patch pumps represent the fastest-growing segment of the insulin delivery market according to ViCentra, which it says is a sign of a broader industry shift toward compact, wearable, and patient-centric solutions.
“ViCentra is redefining insulin pump therapy with a platform that truly centres the user experience – combining clinical performance with design simplicity and wearability,” commented Caaj Greebe, Partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We’re proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”
ViCentra will be in attendance at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place from September 15–19, 2025, at the Vienna Congress & Convention Center (VIECON) in Vienna, Austria. The company will be available to meet with key clinicians, investors, and strategic partners to discuss advancements in insulin delivery and explore strategic partnerships.
